Emgality vs Ajovy: The New Migraine Preventives

Written and medically reviewed by Tae Ho Guak, MD, board-certified neurologist · Reviewed July 2026 · Editorial policy

Hello. I am writing to share hopeful news with those suffering from debilitating migraines that disrupt daily life. While past migraine treatment has been primarily ‘defensive’ — suppressing pain that has already begun — we have now entered an era of ‘proactive intervention’ — blocking the onset of pain itself.

At the center of this shift are next-generation migraine preventive medications: CGRP inhibitors, Emgality and Ajovy.

1. A New Paradigm in Migraine Treatment: Targeting CGRP

Our bodies contain CGRP (calcitonin gene-related peptide), a key substance that triggers migraines. When migraines are severe, this level rises sharply, causing inflammation and pain in the cerebral blood vessels.

Emgality and Ajovy are targeted monoclonal antibody therapies that directly block CGRP ligands or their receptors. In simple terms, they work by proactively preventing the ‘causative substance’ of pain from becoming active.

2. Why Emgality and Ajovy? (Overwhelming Efficacy)

The most significant advantages that patients experience in clinical practice are as follows:

• Remarkable pain reduction effect: According to clinical results, a substantial number of chronic migraine patients who had not benefited from conventional medications experienced a reduction in the average number of migraine days per month by more than half.
• Rapid onset of action: Effects typically begin to appear within the first month after administration, and the speed of return to daily activities is dramatically accelerated.
• Low risk of adverse effects: Common side effects seen with traditional oral preventive medications (antihypertensives, anticonvulsants, etc.) — such as dizziness, drowsiness, and weight gain — are virtually absent. Tolerability is excellent aside from localized reactions such as erythema at the injection site.

3. Personalized Patient Selection: Emgality vs Ajovy

Both medications have outstanding efficacy, but the choice depends on your lifestyle pattern.

• Emgality: Administered once monthly and is essentially the ‘gold standard’ of migraine prevention, with stability and efficacy well-established through extensive prescription data.
• Ajovy: Offers greater flexibility in administration. It can be given once monthly, or alternatively, three doses can be administered simultaneously once every three months (quarterly), making it the optimal choice for those with difficulty attending frequent clinic visits.

Now is the Time to Focus on ‘Prevention’ Rather Than ‘Pain Relief’

Habitually taking pain relievers can actually create a vicious cycle of medication overuse headache. Now, with a single monthly injection to reduce brain hyperexcitability, we must fundamentally improve quality of life.

If persistent headaches have left your life feeling depleted, I encourage you to consult with a neurologist to benefit from this new treatment paradigm. A life without pain is closer than you think.

Related reading:

• What Headache Medications Are Available? (overview of acute and preventive treatments)
• Medication Overuse Headache — The Paradox of Painkillers Causing Headaches
• 2026 Headache Research: Key Updates
• GLP-1 Injections and the Complex Relationship with Headaches (CGRP combo strategies)

References

• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–1088.
• Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine. JAMA. 2018;319(19):1999–2008.
• American Headache Society. Consensus statement: integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021–1039.

This article was written and medically reviewed by Tae Ho Guak, MD, a board-certified neurologist. Last reviewed July 2026. See our editorial policy.